Bobby Sandage

Lightchain Capital LLC operates as single family office of Rodger Riney. It offers venture capital, software development and data science and has worked for major banks, investment firms and startups. The company was founded by Leo Semmelmann and Jan-Erik Flentje in 2007and is headquartered in St. Louis, MO.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Electronic Drug Information Systems Solutions LLC develops electronic drug information systems solutions. It operates a platform that gathers, filters, combines, and presents pharmaceutical intelligence. The firm provides data integration, analytics & presentation, forecasting, and project ranking services. The company is headquartered in St. Louis, MO.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO.

Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Geneoscopy LLC develops diagnostics It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. The firm provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. The company was founded by Andrew Barnell, Erica Barnell and Yiming Kang in 2015 and is headquartered in Saint Louis, MO.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Geneoscopy LLC develops diagnostics It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. The firm provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. The company was founded by Andrew Barnell, Erica Barnell and Yiming Kang in 2015 and is headquartered in Saint Louis, MO.

Geneoscopy LLC develops diagnostics It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. The firm provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. The company was founded by Andrew Barnell, Erica Barnell and Yiming Kang in 2015 and is headquartered in Saint Louis, MO.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023.

Endevica Bio is a biotechnology company that creates first-in-class peptide drug candidates to treat cachexia caused by diseases like cancer, renal failure, and congestive heart failure. The company is based in Columbia, MO. The company's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica Bio's synthetic peptides are stable in plasma and have drug-like characteristics. The company was founded in 2009 by Dr. Kenneth Gruber, who wanted to create synthetic peptides that would show drug-like characteristics. Russ Potterfield has been the CEO of the company since 2020.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Endevica Bio is a biotechnology company that creates first-in-class peptide drug candidates to treat cachexia caused by diseases like cancer, renal failure, and congestive heart failure. The company is based in Columbia, MO. The company's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica Bio's synthetic peptides are stable in plasma and have drug-like characteristics. The company was founded in 2009 by Dr. Kenneth Gruber, who wanted to create synthetic peptides that would show drug-like characteristics. Russ Potterfield has been the CEO of the company since 2020.

Geneoscopy LLC develops diagnostics It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. The firm provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. The company was founded by Andrew Barnell, Erica Barnell and Yiming Kang in 2015 and is headquartered in Saint Louis, MO.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.

Endevica Bio is a biotechnology company that creates first-in-class peptide drug candidates to treat cachexia caused by diseases like cancer, renal failure, and congestive heart failure. The company is based in Columbia, MO. The company's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica Bio's synthetic peptides are stable in plasma and have drug-like characteristics. The company was founded in 2009 by Dr. Kenneth Gruber, who wanted to create synthetic peptides that would show drug-like characteristics. Russ Potterfield has been the CEO of the company since 2020.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023.

Geneoscopy LLC develops diagnostics It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. The firm provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. The company was founded by Andrew Barnell, Erica Barnell and Yiming Kang in 2015 and is headquartered in Saint Louis, MO.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Bioventures LLC is a pharmaceutical company that develops pharmaceutical products. The private company is based in Tulsa, OK and was founded in 2004.

AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

Geneoscopy LLC develops diagnostics It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. The firm provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. The company was founded by Andrew Barnell, Erica Barnell and Yiming Kang in 2015 and is headquartered in Saint Louis, MO.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.

AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023.

Electronic Drug Information Systems Solutions LLC develops electronic drug information systems solutions. It operates a platform that gathers, filters, combines, and presents pharmaceutical intelligence. The firm provides data integration, analytics & presentation, forecasting, and project ranking services. The company is headquartered in St. Louis, MO.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.